Development of a Subunit Vaccine against Duck Hepatitis A Virus Serotype 3
In this study, we sought to develop a subunit vaccine against the increasingly prevalent Duck hepatitis A virus serotype 3 (DHAV-3). The VP1 protein of DHAV-3 and a truncated version containing the C-terminal region of VP1, termed VP1-C, were expressed recombinantly in Escherichia coli as vaccine an...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028120/ https://www.ncbi.nlm.nih.gov/pubmed/35455272 http://dx.doi.org/10.3390/vaccines10040523 |
_version_ | 1784691537535303680 |
---|---|
author | Truong, Trang-Nhu Cheng, Li-Ting |
author_facet | Truong, Trang-Nhu Cheng, Li-Ting |
author_sort | Truong, Trang-Nhu |
collection | PubMed |
description | In this study, we sought to develop a subunit vaccine against the increasingly prevalent Duck hepatitis A virus serotype 3 (DHAV-3). The VP1 protein of DHAV-3 and a truncated version containing the C-terminal region of VP1, termed VP1-C, were expressed recombinantly in Escherichia coli as vaccine antigens. For enhanced immune response, a truncated version of flagellin, nFliC, was included as vaccine adjuvant. Ducklings were vaccinated once for immune response analysis and challenge test. Results showed that VP1-C elicited a higher level of virus-specific antibody response and neutralization titer than VP1. The addition of nFliC further enhanced the antibody response. In terms of cellular immune response, the VP1-C + nFliC vaccine elicited the highest level of T cell proliferation among the vaccine formulations tested. Examination of the cytokine expression profile showed that peripheral blood mononuclear cells from the VP1-C + nFliC vaccine group expressed the highest levels of pro-inflammatory (IL-6) and TH-1 type (IL-12 and IFN-γ) cytokines. Finally, in a DHAV-3 challenge test, the VP1-C + nFliC vaccine provided a 75% protection rate (n = 8), in contrast to 25% for the VP1 vaccine. In conclusion, E. coli-expressed VP1-C has been shown to be a promising antigen when combined with nFliC and may be further developed as a single-dose subunit vaccine against DHAV-3. |
format | Online Article Text |
id | pubmed-9028120 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-90281202022-04-23 Development of a Subunit Vaccine against Duck Hepatitis A Virus Serotype 3 Truong, Trang-Nhu Cheng, Li-Ting Vaccines (Basel) Article In this study, we sought to develop a subunit vaccine against the increasingly prevalent Duck hepatitis A virus serotype 3 (DHAV-3). The VP1 protein of DHAV-3 and a truncated version containing the C-terminal region of VP1, termed VP1-C, were expressed recombinantly in Escherichia coli as vaccine antigens. For enhanced immune response, a truncated version of flagellin, nFliC, was included as vaccine adjuvant. Ducklings were vaccinated once for immune response analysis and challenge test. Results showed that VP1-C elicited a higher level of virus-specific antibody response and neutralization titer than VP1. The addition of nFliC further enhanced the antibody response. In terms of cellular immune response, the VP1-C + nFliC vaccine elicited the highest level of T cell proliferation among the vaccine formulations tested. Examination of the cytokine expression profile showed that peripheral blood mononuclear cells from the VP1-C + nFliC vaccine group expressed the highest levels of pro-inflammatory (IL-6) and TH-1 type (IL-12 and IFN-γ) cytokines. Finally, in a DHAV-3 challenge test, the VP1-C + nFliC vaccine provided a 75% protection rate (n = 8), in contrast to 25% for the VP1 vaccine. In conclusion, E. coli-expressed VP1-C has been shown to be a promising antigen when combined with nFliC and may be further developed as a single-dose subunit vaccine against DHAV-3. MDPI 2022-03-28 /pmc/articles/PMC9028120/ /pubmed/35455272 http://dx.doi.org/10.3390/vaccines10040523 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Truong, Trang-Nhu Cheng, Li-Ting Development of a Subunit Vaccine against Duck Hepatitis A Virus Serotype 3 |
title | Development of a Subunit Vaccine against Duck Hepatitis A Virus Serotype 3 |
title_full | Development of a Subunit Vaccine against Duck Hepatitis A Virus Serotype 3 |
title_fullStr | Development of a Subunit Vaccine against Duck Hepatitis A Virus Serotype 3 |
title_full_unstemmed | Development of a Subunit Vaccine against Duck Hepatitis A Virus Serotype 3 |
title_short | Development of a Subunit Vaccine against Duck Hepatitis A Virus Serotype 3 |
title_sort | development of a subunit vaccine against duck hepatitis a virus serotype 3 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9028120/ https://www.ncbi.nlm.nih.gov/pubmed/35455272 http://dx.doi.org/10.3390/vaccines10040523 |
work_keys_str_mv | AT truongtrangnhu developmentofasubunitvaccineagainstduckhepatitisavirusserotype3 AT chengliting developmentofasubunitvaccineagainstduckhepatitisavirusserotype3 |